ImmunoPrecise Antibodies Ltd. (IPA)

ImmunoPrecise Antibodies Balance Sheet

Financials in millions CAD. Fiscal year is May - April.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	8.37	30.05	41.84	2.69	5.54
Cash & Cash Equivalents	8.37	30.05	41.84	2.69	5.54
Cash Growth	-72.16%	-28.18%	1454.74%	-51.42%	-
Receivables	0.63	0.63	3.63	3.66	1.95
Inventory	2.06	1.62	1.2	0.82	0.8
Other Current Assets	5.73	5.18	2.19	0.53	0.27
Total Current Assets	16.79	37.47	48.86	7.7	8.56
Property, Plant & Equipment	10.39	3.56	4.02	3.08	1.64
Long-Term Investments	0.12	0.14	0.11	0.12	0.09
Goodwill and Intangibles	50.1	52.03	13.84	16.19	18.11
Other Long-Term Assets	0.42	0.45	0.13	0.17	0.07
Total Long-Term Assets	61.02	56.18	18.1	19.56	19.91
Total Assets	77.81	93.65	66.96	27.26	28.46
Accounts Payable	3.39	4.77	3.01	1.77	1.59
Deferred Revenue	0.98	1.03	1.11	1.48	0.72
Current Debt	1.12	2.3	0.99	2.87	2.83
Other Current Liabilities	0.44	1.19	0.96	1.82	2.06
Total Current Liabilities	5.92	9.29	6.07	7.93	7.2
Long-Term Debt	6.15	0.47	2.47	1.64	0.1
Other Long-Term Liabilities	7.94	8.6	1.49	2.61	3.09
Total Long-Term Liabilities	14.09	9.07	3.96	4.25	3.19
Total Liabilities	20.01	18.36	10.04	12.18	10.39
Total Debt	7.27	2.77	3.46	4.51	2.93
Debt Growth	162.63%	-19.96%	-23.33%	54.04%	-
Retained Earnings	-73.09	-46.53	-29.82	-22.48	-17.48
Comprehensive Income	2.63	-2.48	-0.69	-0.3	-0.23
Shareholders' Equity	57.8	75.29	56.92	15.09	18.07
Net Cash / Debt	1.1	27.28	38.38	-1.82	2.61
Net Cash / Debt Growth	-95.97%	-28.92%	-	-	-
Net Cash Per Share	0.04	1.39	2.33	-0.13	0.21
Working Capital	10.87	28.18	42.79	-0.23	1.35
Book Value Per Share	2.32	3.82	3.46	1.11	1.44

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).